Cargando…
表观遗传机制在非小细胞肺癌靶向治疗获得性耐药中的研究进展
Patients with oncogenic driver alterations of non-small cell lung cancer (NSCLC) can benefit from targeted therapy, but acquired resistance is inevitable ultimately. Epigenetic modifications, including DNA methylation, histone modifications, non-coding RNA-mediated regulate and chromatin remodeling,...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560982/ https://www.ncbi.nlm.nih.gov/pubmed/34696542 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.34 |